Telix's Illuccix PSMA-PET imaging agent approved in France for prostate cancer detection

From GlobeNewswire: 2025-04-28 18:30:00

Telix Pharmaceuticals Limited has received marketing authorization in France for its prostate cancer PET imaging agent, Illuccix, for detecting and localizing PSMA-positive lesions in adults with prostate cancer. The approval is based on robust clinical data from the VISION trial, enabling hospitals to prepare PSMA-PET scans on-site. PSMA-PET imaging offers superior accuracy in staging primary disease and assessing biochemical recurrence, providing clinicians with crucial information for effective diagnosis and disease management. The approval of Illuccix in France will help address access challenges and support timely and reliable prostate cancer care. The product is designed to meet the growing demand for PSMA-PET in Europe, providing a convenient and efficient imaging solution.



Read more at GlobeNewswire: Telix’s Illuccix PSMA-PET Imaging Agent Approved in France